Countdown to IPBC Korea 2023
Just one month until IP leaders will gather in Seoul for an agenda tackling policy developments, market trends, and commercial pressures
Just one month until IP leaders will gather in Seoul for an agenda tackling policy developments, market trends, and commercial pressures
Opinion: Popular attacks on America’s life sciences patent system are highly misleading
Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112
The Senate Judicial Committee has advanced several IP bills targeting life sciences rights owners
13 February 2023
Alexander Haertel talks about the Industry Patent Quality Charter, the UPC and German injunctions in an exclusive IAM interview
09 February 2023
From the archives: Lord Kitchin's in-depth interview with IAM
03 February 2023
For companies, policy makers and service providers, the growing importance of know-how as a quantifiable asset presents dangers and opportunities
02 February 2023
President can now pick out foreign entities and subject them to a series of sanctions
01 February 2023
With Amgen’s biosimilar finally set to launch in the US, IAM looks back on arguably the most interesting set of pharma patent disputes in recent years
30 January 2023
Saturday Opinion: Supporting the legality of fair non-compete agreements will enhance foreign investors’ reasonable expectations of protection by the US IP system
28 January 2023
Director General José Sánchez Pérez meets with local lawyers to discuss enforcement and implementation of IP law
25 January 2023
Individual inventors and innovative small businesses have a compelling story to tell about a system that does not work for them, but it has yet to hit home
19 January 2023
America risks losing ground in the next tech revolution he warns in an interview with Burford Capital Managing Director Katharine Wolanyk
17 January 2023
Unlock unlimited access to all IAM content